Allergan Inc. (AGN)
AGN (NYSE:Drugs)
$101.49
+0.01
+0.01%
Today's Range: 100.66 - 102.17 |
AGN Avg Daily Volume: 2,014,900
| Last Update: 06/18/13 - 4:03 PM EDT |
| Volume: 1,855,963 |
| YTD Performance: 10.63%
|
| Open: $101.80 |
| Previous Close: $101.48 |
| 52 Week Range: $81.28 -
$116.45 |
| Oustanding Shares: 296,400,416 |
| Market Cap: 29,977,938,074 |
6-Month Chart
TheStreet Ratings Grade for AGN
| Buy |
Hold
|
Sell
|
| A+ |
A |
A- |
B+ |
B |
B- |
C+ |
C |
C- |
D+ |
D |
D- |
E+ |
E |
E- |
F |
Analysts Ratings
| Historical Rec |
Current |
1 Mo. Ago |
2 Mo. Ago |
3 Mo. Ago |
| Strong Buy |
14 |
14 |
13 |
13 |
| Moderate Buy |
2 |
2 |
3 |
3 |
| Hold |
8 |
8 |
8 |
8 |
| Moderate Sell |
0 |
0 |
0 |
0 |
| Strong Sell |
0 |
0 |
0 |
0 |
| Mean Rec. |
1.75 |
1.75 |
1.77 |
1.77 |
| Latest Dividend: |
0.05 |
| Latest Dividend Yield: |
0.20% |
| Dividend Ex-Date: |
05/21/13 |
| Price Earnings Ratio: |
27.12 |
|
| Price Earnings Comparisons: |
| AGN |
Sector Avg. |
S&P 500 |
| 27.12 |
35.10 |
17.70 |
| Price Performance History (%Change): |
| 3 Mo |
1 Yr |
3 Y |
|
-6.88%
|
9.77%
|
65.14%
|
|
| GROWTH |
12 Mo |
3 Yr |
CAGR |
| Revenue |
7.10 |
0.29 |
0.09 |
| Net Income |
0.00 |
0.77 |
0.21 |
| EPS |
18.90 |
0.78 |
0.21 |
| Earnings for AGN: |
| EBITDA |
1.89B |
| Revenue |
5.81B |
|
Average Earnings Estimates
;Qtr (09/13);FY (12/13);FY (12/14)&HEADING_LIST1=Qtr (06/12);Qtr (09/12);FY (12/12);FY (12/13)) |
|
| Average Estimate |
$1.20 |
$1.21 |
$4.75 |
$5.46 |
| Number of Analysts |
15 |
15 |
18 |
18 |
| High Estimate |
$1.26 |
$1.26 |
$4.77 |
$5.70 |
| Low Estimate |
$1.18 |
$1.18 |
$4.71 |
$5.28 |
| Prior Year |
$1.07 |
$1.06 |
$4.14 |
$4.75 |
| Growth Rate (Year over Year) |
12.15% |
14.47% |
14.63% |
15.06% |
May 28, 2013 | 8:10 AM EDT
AGN was placed on the US 1 list, according to Bank of America/Merrill Lynch. Stock is attractive, following a 14% pullback this month. ...
May 08, 2013 | 6:00 AM EDT
May 02, 2013 | 8:06 AM EDT
AGN was upgraded from Neutral to Buy, Lazard Capital Markets said. $115 price target. Selloff appears overdone.
| May 01, 2013 | 12:49 PM EDT
Focusing on near-term drug stock earnings is the wrong move.
Apr 17, 2013 | 3:15 PM EDT
Feb 14, 2013 | 6:34 AM EST
Leerink Swann Global Healthcare Conference (Day 2 of 2) - 02/13/13 - 02/14/13 New York, NY
Feb 07, 2013 | 7:57 AM EST
AGN price target raised to $124, Citigroup said. Core franchises continue to deliver double digit growth. Buy rating.
Feb 06, 2013 | 11:26 AM EST
Feb 06, 2013 | 8:13 AM EST
Feb 06, 2013 | 8:00 AM EST
Shares of AGN now seen reaching $100, Jefferies said. Estimates also raised on resiliency of model in the fourth quarter. Hold rating.
...
